CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in <i>KIT</i> D816V<sup>+</sup> Neoplastic Mast Cells

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in <i>KIT</i> D816V<sup>+</sup> Neoplastic Mast Cells

In most patients with advanced systemic mastocytosis (AdvSM), neoplastic mast cells (MC) express <i>KIT</i> D816V. However, despite their disease-modifying potential, KIT D816V-targeting drugs, including midostaurin and avapritinib, may not produce long-term remissions in all patients. C...

Full description

Bibliographic Details
Main Authors: Mathias Schneeweiss-Gleixner, Yüksel Filik, Gabriele Stefanzl, Daniela Berger, Irina Sadovnik, Karin Bauer, Dubravka Smiljkovic, Gregor Eisenwort, Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Ana-Iris Schiefer, Juliana Schwaab, Mohamad Jawhar, Andreas Reiter, Wolfgang R. Sperr, Michel Arock, Peter Valent, Karoline V. Gleixner
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Cancers
Subjects:
systemic mastocytosis
<i>KIT</i> D816V
midostaurin
avapritinib
CDK4/CDK6
palbociclib
Online Access:https://www.mdpi.com/2072-6694/14/13/3070

Internet

https://www.mdpi.com/2072-6694/14/13/3070

Similar Items